MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Pieris Pharmaceuticals Company Profile (NASDAQ:PIRS)

Consensus Ratings for Pieris Pharmaceuticals (NASDAQ:PIRS) (?)
Ratings Breakdown: 3 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.67 (438.30% upside)

Analysts' Ratings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Show:
DateFirmActionRatingPrice TargetActions
3/24/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$10.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2015OppenheimerReiterated RatingBuy$8.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Pieris Pharmaceuticals (NASDAQ:PIRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q116($0.12)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q415($0.12)($0.07)$3.27 million$2.14 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.11)($0.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015Q215($0.14)($0.12)$160.24 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.03$0.03$0.03
Q2 20162($0.16)($0.12)($0.14)
Q3 20162($0.14)($0.12)($0.13)
Q4 20162($0.14)($0.12)($0.13)
(Data provided by Zacks Investment Research)
Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/14/2016Louis MatisSVPBuy10,000$1.70$17,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Darlene M Deptula-HicksCFOBuy5,000$1.66$8,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016Stephen S YoderCEOBuy6,000$1.68$10,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Pieris Pharmaceuticals (NASDAQ:PIRS)
DateHeadline
06/29/16 08:38 AMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Company Rating and Target Watch - Telanagana Press
06/27/16 09:59 AMShare Update and Earnings Review for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph
06/24/16 05:54 PMHow Many Pieris Pharmaceuticals Inc (NASDAQ:PIRS)'s Analysts Are Bullish? - Press Telegraph
06/24/16 08:27 AMPieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Short Interest Increased By 18.12% - Press Telegraph
06/24/16 08:27 AMCovering the Bases on Pieris Pharmaceuticals Inc (NASDAQ:PIRS): Where is the Stock Going? - Press Telegraph
06/24/16 08:27 AMPieris Pharmaceuticals, Inc. (PIRS) Current Analyst Ratings - Fiscal Standard
06/24/16 08:27 AMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Earnings Glance and Target Price Review - Engelwood Daily
06/23/16 08:30 AMEquity Research and Technical Review on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Press Telegraph
06/22/16 05:48 PMVeriFone Systems, Inc. (NYSE:PAY) Declined -1.38%: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), American Water ... - KC Register
06/14/16 06:59 AMPieris Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences - [Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced today ...
06/09/16 04:23 PMPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events -
06/08/16 06:15 PMPieris Pharmaceuticals Announces Closing of $16.5 Million Private Placement
06/08/16 04:02 PMPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/04/16 08:45 AMPieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Short Interest Decreased By 12.32% - HNN
06/03/16 08:44 AMShare Rating Focus on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - HNN - Share Rating Focus on Pieris Pharmaceuticals Inc (NASDAQ:PIRS)HNNThis stock research may entail following what professional equity analysts think about the company. Presently, Wall Street analysts have given a consensus stock rating of 1 on shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS). Covering analysts will ...and more »
06/03/16 08:00 AMPieris Pharmaceuticals Announces $16.5 Million Private Placement - [Marketwired] - Pieris Pharmaceuticals, Inc. announced today that it entered into a securities purchase agreement for a private placement with a select group of institutional investors, including lead investor BVF Partners ...
06/02/16 06:15 PMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Stock Update & Estimates - Stock Tick Tock - Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to post earnings of $-0.14 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be ...and more »
06/02/16 08:49 AMTarget Price and Stock Performance Rundown for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - HNN - Target Price and Stock Performance Rundown for Pieris Pharmaceuticals Inc (NASDAQ:PIRS)HNNDuring the latest trading session, Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares traded +1.05%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
06/01/16 02:22 PMPieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/30/16 06:23 PMPerformance at a Glance on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - HNN - Performance at a Glance on Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)'s stock has performed at various points in its past ...and more »
05/30/16 06:23 PMNext Weeks Broker Price Targets For Pieris Pharmaceuticals, Inc. (PIRS) - Share Trading News - Next Weeks Broker Price Targets For Pieris Pharmaceuticals, Inc. (PIRS)Share Trading News08/12/2015 – JMP Securities began new coverage on Pieris Pharmaceuticals, Inc. giving the company a “market outperform” rating. They now have a USD 10 price target on the stock. Pieris Pharmaceuticals, Inc. has a 50 day moving average of 1.99 and a ...Pieris Pharmaceuticals Incorporated (NASDAQ:PIRS) Sellers Covered 12.32% of Their ShortsFranklin Independentall 2 news articles »
05/20/16 01:41 PMAnalyst Rating Check on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Wall Street Hints and News - Analyst Rating Check on Pieris Pharmaceuticals Inc (NASDAQ:PIRS)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 1 on shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS). Analysts that cover the ...and more »
05/19/16 01:52 PMShare Performance and Target Price Review for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Wall Street Hints and News - Share Performance and Target Price Review for Pieris Pharmaceuticals Inc (NASDAQ:PIRS)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Pieris Pharmaceuticals Inc ...and more »
05/19/16 01:52 PMPieris Pharmaceuticals: The Blockbuster In Antibody Mimetics - Seeking Alpha - Pieris Pharmaceuticals: The Blockbuster In Antibody MimeticsSeeking AlphaWith a market cap of just over $65 million USD, they qualify as a small-cap pharmaceutical. They currently have not progressed into Phase III trials, giving them a relatively early and risky status. However, we are strongly bullish on the company, and ...Analyst Coverage: Pieris Pharmaceuticals, Inc. (PIRS)Risers & Fallersall 2 news articles »
05/18/16 02:30 PMPIRS: PRS-343 Shows Efficacy in Humanized Mouse Cancer Model… -
05/18/16 01:31 PMPieris Pharmaceuticals: The Blockbuster In Antibody Mimetics - Pieris ... CGI Pharmaceuticals was acquired from Gilead (NASDAQ:GILD) in 2010. Louis Matis' previous companies have an impressive track record. The CFO, Darlene Deptula-Hicks, has an extensive track record as working CFO of Microline Surgical, Inc ...
05/16/16 01:28 PMAfter Last Week What Do Analysts Think Of Pieris Pharmaceuticals, Inc. (PIRS) - Share Trading News - After Last Week What Do Analysts Think Of Pieris Pharmaceuticals, Inc. (PIRS)Share Trading NewsThey now have a USD 10 price target on the stock. The share price of Pieris Pharmaceuticals, Inc. (PIRS) was down -1.72% during the last trading session, with a day high of 1.71. 81895 shares were traded on Pieris Pharmaceuticals, Inc.'s last session.and more »
05/13/16 12:46 PMPerformance Recap and Target Perspective on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Wall Street Hints and News - Performance Recap and Target Perspective on Pieris Pharmaceuticals Inc (NASDAQ:PIRS)Wall Street Hints and NewsIn the latest trading session, shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) moved -5.6000%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, ...and more »
05/13/16 12:46 PMConsensus Rating Review for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - Wall Street Hints and News - Consensus Rating Review for Pieris Pharmaceuticals Inc (NASDAQ:PIRS)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/12/16 12:45 PMPieris Pharmaceuticals Inc (PIRS) Issues Quarterly Earnings Results - Washington News Wire - Washington News WirePieris Pharmaceuticals Inc (PIRS) Issues Quarterly Earnings ResultsWashington News WirePieris Pharmaceuticals logo Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its quarterly earnings results on Wednesday. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02, Market Beat ...Pieris Pharmaceuticals Inc (PIRS) Posts Earnings Results, Beats Estimates By $0.02 EPSNewsWay 21Pieris Pharmaceuticals Reports Q1 Loss Wider Than Street, Revenue Jumps Year-on-Year (NASDAQ:PIRS)Sonoran Weekly ReviewPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) To Report EarningsRisers & FallersB.O.D.Y Confidential -Money Morningall 7 news articles »
05/12/16 08:41 AMPIERIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/11/16 04:04 PMPieris Pharmaceuticals reports 1Q loss -
05/11/16 04:02 PM5:02 pm Pieris Pharmaceuticals reports Q1 results -
05/11/16 04:00 PMPieris Pharmaceuticals Reports Financial Results and Corporate Update for the First Quarter Ended March 31, 2016 - [Marketwired] - Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, today reported ...
05/10/16 12:59 PMPieris Pharmaceuticals, Inc. (NASDAQ:PIRS) To Release Earnings On Wednesday - Share Trading News - Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) To Release Earnings On WednesdayShare Trading NewsAt the moment 4 analysts are watching Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), 1 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”. Looking forward, for the quarter ending Jun-16, 2 analysts have a mean sales target of 0.25 ...and more »
05/07/16 12:34 PMAverage Analyst Rating for Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - B.O.D.Y Confidential - Average Analyst Rating for Pieris Pharmaceuticals Inc (NASDAQ:PIRS)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/02/16 01:37 PMBroker Outlook For The Week Ahead: Pieris Pharmaceuticals, Inc. (PIRS) - Share Trading News - Broker Outlook For The Week Ahead: Pieris Pharmaceuticals, Inc. (PIRS)Share Trading NewsThey now have a USD 10 price target on the stock. The share price of Pieris Pharmaceuticals, Inc. (PIRS) was down -1.95% during the last trading session, with a day high of 2.10. 28365 shares were traded on Pieris Pharmaceuticals, Inc.'s last session.and more »
04/29/16 12:37 PMShare Performance and Target Price Review Pieris Pharmaceuticals Inc (NASDAQ:PIRS) - B.O.D.Y Confidential - Share Performance and Target Price Review Pieris Pharmaceuticals Inc (NASDAQ:PIRS)B.O.D.Y ConfidentialDuring the most recent trading session, shares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) ended up with a move of +4.88%. Sell-side analysts have given a consensus target price of $8.67 on company shares. Target price projections may differ greatly ...and more »
04/29/16 12:37 PMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Share Rating Recap - B.O.D.Y Confidential - Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Share Rating RecapB.O.D.Y ConfidentialShares of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Analyst Rating ReviewThe Postall 256 news articles »
04/27/16 01:25 PMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Wall Street Rating in Focus - News Tribune - Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Wall Street Rating in FocusNews TribuneZacks.com, founded by Len Zacks, a Mathematics Ph.D. from M.I.T. who discovered that earnings estimate revisions are the most powerful force impacting stock prices, track 3 equity research firms that cover shares of Pieris Pharmaceuticals Inc ...and more »
04/27/16 01:25 PMPieris Pharmaceuticals Inc (NASDAQ:PIRS) Analyst Rating Review - The Post - Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Analyst Rating ReviewThe PostCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 3 analysts that have provided ratings for Pieris Pharmaceuticals Inc (NASDAQ:PIRS). 3 have rated the stock a ...and more »
04/27/16 01:25 PMPieris Pharmaceuticals, Inc. (PIRS) Latest Broker Views - Risers & Fallers - Pieris Pharmaceuticals, Inc. (PIRS) Latest Broker ViewsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Pieris Pharmaceuticals, Inc. (PIRS). According to the latest broker reports outstanding on Wednesday 27th of April, 0 analysts have a rating of “strong buy”, 0 ...Pieris Pharmaceuticals to Host First Quarter 2016 Investor Call and Corporate Update on May 12, 2016Marketwired (press release)all 2 news articles »
04/27/16 07:00 AMPieris Pharmaceuticals to Host First Quarter 2016 Investor Call and Corporate Update on May 12, 2016 - [Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a first quarter 2016 investor conference call on Thursday, May 12, 2016 ...
04/25/16 01:33 PMPieris Pharmaceuticals, Inc. (PIRS) Updated Broker Ratings - Risers & Fallers - Pieris Pharmaceuticals, Inc. (PIRS) Updated Broker RatingsRisers & FallersA number of investment brokers have recently updated their price targets on shares of Pieris Pharmaceuticals, Inc. (PIRS). According to the latest broker reports outstanding on Monday 25th of April, 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
04/22/16 01:25 PMLatest Analyst Ratings For Pieris Pharmaceuticals, Inc. (PIRS) - Share Trading News - Latest Analyst Ratings For Pieris Pharmaceuticals, Inc. (PIRS)Share Trading News12/08/2015 – Pieris Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 10 price target on the stock. 08/13/2015 – Pieris Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Roth ...
03/28/16 10:50 AMPieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q4, 2015 By the Numbers -
03/24/16 11:11 AMPieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: 2015 By the Numbers -
03/22/16 03:18 PMPieris Pharmaceuticals reports 4Q loss -
03/03/16 07:00 AMPieris Pharmaceuticals to Host Full-Year 2015 Investor Call and Corporate Update on March 23, 2016 - [Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, will host a year-end 2015 investor conference call on Wednesday, March 23, 2016 ...
03/02/16 07:00 AMPieris Pharmaceuticals to Present at the Cowen & Company 36th Annual Healthcare Conference on March 9th at 10:00 am ET - [Marketwired] - Pieris Pharmaceuticals, Inc. , a biotechnology company advancing its proprietary Anticalin® bio therapeutic technologies, announced today that CEO Stephen Yoder will present a corporate overview of the ...
About Pieris Pharmaceuticals

Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PIRS
  • CUSIP:
Key Metrics:
  • Previous Close: $1.61
  • 50 Day Moving Average: $1.74
  • 200 Day Moving Average: $1.89
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $64.13M
  • Current Quarter EPS Consensus Estimate: $-0.54 EPS
Additional Links:
Pieris Pharmaceuticals (NASDAQ:PIRS) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha